A previous study demonstrated that severe and life-threatening bleeding occurred in 70% to 90% of AHA patients, and the fatality rate was 5% to 10%.[1] Hemostatic agents such as bypassing agents, rFVIIa, and activated prothrombin complex concentrates are considered as first-line treatment for bleeding episodes in AHA patients.[1] In patients with lower titers of FVIII inhibitor (<5 BU/ml), human FVIII replacement and desmopressin might be adequate. This evidence concerns the gene F8 and autoimmune hemolytic anemia.